相似文献
1
Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?
Neuro Oncol. 2025 Jan 12;27(1):302-305. doi: 10.1093/neuonc/noae225.
2
Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Expert Rev Vaccines. 2020 May;19(5):407-417. doi: 10.1080/14760584.2020.1750376. Epub 2020 Apr 17.
3
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.
Front Oncol. 2024 Sep 27;14:1454370. doi: 10.3389/fonc.2024.1454370. eCollection 2024.
4
Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials.
J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x.
5
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
6
7
A review of glioblastoma immunotherapy.
J Neurooncol. 2021 Jan;151(1):41-53. doi: 10.1007/s11060-020-03448-1. Epub 2020 Apr 6.
8
The current and future aspects of glioblastoma: Immunotherapy a new hope?
Eur J Neurosci. 2021 Aug;54(3):5120-5142. doi: 10.1111/ejn.15343. Epub 2021 Jun 29.
9
Vaccination in the immunotherapy of glioblastoma.
Hum Vaccin Immunother. 2018 Feb 1;14(2):255-268. doi: 10.1080/21645515.2017.1388481. Epub 2017 Dec 11.
10
Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
CNS Oncol. 2015;4(2):63-9. doi: 10.2217/cns.14.54.
引用本文的文献
1
Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation.
Front Immunol. 2025 Aug 6;16:1635331. doi: 10.3389/fimmu.2025.1635331. eCollection 2025.
本文引用的文献
1
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Nat Commun. 2024 Aug 11;15(1):6870. doi: 10.1038/s41467-024-51315-8.
2
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.
Neuro Oncol. 2024 May 3;26(5):796-810. doi: 10.1093/neuonc/noae005.
3
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Nat Med. 2023 Oct;29(10):2586-2592. doi: 10.1038/s41591-023-02555-6. Epub 2023 Sep 21.
4
External control arms in oncology: current use and future directions.
Ann Oncol. 2022 Apr;33(4):376-383. doi: 10.1016/j.annonc.2021.12.015. Epub 2022 Jan 10.
5
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Lancet Oncol. 2021 Oct;22(10):e456-e465. doi: 10.1016/S1470-2045(21)00488-5.
6
Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade.
Front Oncol. 2020 Jul 3;10:840. doi: 10.3389/fonc.2020.00840. eCollection 2020.
7
Longitudinal molecular trajectories of diffuse glioma in adults.
Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.
8
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19.
9
Lomustine and Bevacizumab in Progressive Glioblastoma.
N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.
10
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.
Zotero 插件